Generated by All in One SEO v4.9.6.2, this is an llms.txt file, used by LLMs to index the site.

# Frontier Medicines

Boldly Advancing Science to Defeat Disease

## Sitemaps

- [XML Sitemap](https://www.frontiermeds.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Frontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of Directors](https://www.frontiermeds.com/press-release/frontier-medicines-appoints-veteran-drug-development-leader-david-r-epstein-to-board-of-directors/)
- [Frontier Medicines Announces Exclusive Licensing Agreement for FMC-220, a First-in-Class Covalent p53 Y220C Activator, with LG Chem, Ltd.](https://www.frontiermeds.com/press-release/frontier-medicines-announces-exclusive-licensing-agreement-for-fmc-220-a-first-in-class-covalent-p53-y220c-activator-with-lg-chem-ltd/)
- [Frontier Medicines to Present Findings on PI3Kα-RAS Breaker FMC-242 and AI-Powered Frontier™ Platform at AACR Annual Meeting 2026](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-findings-on-pi3kα-ras-breaker-fmc-242-and-ai-powered-frontier-platform-at-aacr-annual-meeting-2026/)
- [Frontier Medicines Announces Publication in Nature Communications Highlighting a Novel Method that Enables Next-Generation Covalent Medicines](https://www.frontiermeds.com/press-release/frontier-medicines-announces-publication-in-nature-communications-highlighting-a-novel-method-that-enables-next-generation-covalent-medicines/)
- [Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference/)
- [J.P. Morgan](https://www.frontiermeds.com/events/jp-morgan/)
- [Frontier Medicines Corporate Presentation](https://www.frontiermeds.com/presentations/events-presentations-placeholder-4/) - Frontier Medicines Corporate Presentation
- [Frontier Medicines Presents Preclinical Data from Three Programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets](https://www.frontiermeds.com/press-release/frontier-medicines-presents-preclinical-data-from-three-programs-at-the-37th-aacr-nci-eortc-international-conference-on-molecular-targets/)
- [Structural basis for DCAF2 as a novel E3 ligase for PROTAC-mediated targeted protein degradation](https://pubmed.ncbi.nlm.nih.gov/41045927/#new_tab)
- [A practical method for determining the rate of covalent modification of fragments and leads](https://pubmed.ncbi.nlm.nih.gov/41413335/#new_tab)
- [Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective](https://pubmed.ncbi.nlm.nih.gov/41290421/#new_tab)
- [Where and how to house big data on small fragments](https://pubmed.ncbi.nlm.nih.gov/40325009/#new_tab)
- [Fragment-to-Lead Medicinal Chemistry Publications in 2023](https://pubmed.ncbi.nlm.nih.gov/39761118/#new_tab)
- [Fragment-to-Lead Medicinal Chemistry Publications in 2022](https://pubmed.ncbi.nlm.nih.gov/38289623/#new_tab)
- [Fragment-to-Lead Medicinal Chemistry Publications in 2021](https://pubmed.ncbi.nlm.nih.gov/36622056/#new_tab)
- [Fragment-to-Lead Medicinal Chemistry Publications in 2020](https://pubmed.ncbi.nlm.nih.gov/34928151/#new_tab)
- [Targeting mutant KRAS](https://pubmed.ncbi.nlm.nih.gov/33838397/#new_tab)
- [Frontier Medicines Announces Third Precision Oncology Development Candidate](https://www.frontiermeds.com/press-release/frontier-medicines-announces-third-precision-oncology-development-candidate/)
- [Frontier Medicines Announces Publication in Structure Highlighting Novel E3 Ligase DCAF2 can be Harnessed for Targeted Protein Degradation](https://www.frontiermeds.com/press-release/frontier-medicines-announces-publication-in-structure-highlighting-novel-e3-ligase-dcaf2-can-be-harnessed-for-targeted-protein-degradation/)
- [Frontier Medicines to Participate in September Investor Conferences](https://www.frontiermeds.com/press-release/frontier-medicines-to-participate-in-september-investor-conferences/)
- [Frontier Medicines to Present at the Cantor Global Healthcare Conference](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-at-the-cantor-global-healthcare-conference/)
- [Frontier Medicines to Present at Two Upcoming Investor Conferences](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-at-two-upcoming-investor-conferences/)
- [Frontier Medicines Appoints Seasoned Executive Gregory Chow as Chief Financial Officer](https://www.frontiermeds.com/press-release/frontier-medicines-appoints-seasoned-executive-gregory-chow-as-chief-financial-officer/)
- [Frontier Medicines Appoints Drug Development Expert David M. Goldstein, Ph.D., to its Board of Directors](https://www.frontiermeds.com/press-release/frontier-medicines-appoints-drug-development-expert-david-m-goldstein-ph-d-to-its-board-of-directors/)
- [Frontier Medicines to Present at the 39th Annual J.P. Morgan Healthcare Conference](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference/)
- [Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets](https://www.frontiermeds.com/press-release/frontier-medicines-and-abbvie-establish-global-partnership-to-discover-and-develop-novel-therapies-and-e3-degraders-against-difficult-to-drug-targets/)
- [Chemical & Engineering News Names Frontier Medicines One of Its 10 Chemistry Start-Ups to Watch](https://www.frontiermeds.com/press-release/chemical-engineering-news-names-frontier-medicines-one-of-its-10-chemistry-start-ups-to-watch/)
- [FierceBiotech Names Frontier Medicines One of Its “Fierce 15” Biotech Companies of 2019](https://www.frontiermeds.com/press-release/fiercebiotech-names-frontier-medicines-one-of-its-fierce-15-biotech-companies-of-2019/)
- [Frontier Medicines Announces Three Executive Hires: Chief Scientific Officer, Chief Technology Officer & Head of Degrader Technologies](https://www.frontiermeds.com/press-release/frontier-medicines-announces-three-executive-hires-chief-scientific-officer-chief-technology-officer-head-of-degrader-technologies/)
- [Frontier Medicines Launches with $67 Million to Develop Novel Medicines that Drug the “Undruggable” Targets Driving Human Disease](https://www.frontiermeds.com/press-release/frontier-medicines-launches-with-67-million-to-develop-novel-medicines-that-drug-the-undruggable-targets-driving-human-disease/)
- [Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline](https://www.frontiermeds.com/press-release/frontier-medicines-raises-88-5-million-series-b-financing-to-advance-precision-oncology-and-targeted-protein-degradation-pipeline/)
- [Frontier Medicines to Present at Two Upcoming Investor Conferences in November](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-at-two-upcoming-investor-conferences-in-november/)
- [Frontier Medicines Announces the Appointment of Marguerite Hutchinson, J.D., as Chief Business Officer](https://www.frontiermeds.com/press-release/frontier-medicines-announces-the-appointment-of-marguerite-hutchinson-j-d-as-chief-business-officer/)
- [Frontier Medicines to Present at the RBC Capital Markets Healthcare Private Company Virtual Conference](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-at-the-rbc-capital-markets-healthcare-private-company-virtual-conference/)
- [Frontier Medicines to Present at the 40th Annual J.P. Morgan Healthcare Conference](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference/)
- [Frontier Medicines Announces Advancement of First Program Under Global Partnership with AbbVie](https://www.frontiermeds.com/press-release/frontier-medicines-announces-advancement-of-first-program-under-global-partnership-with-abbvie/)
- [Frontier Medicines Announces Renowned Physician Scientist Piro Lito, M.D., Ph.D., Joins Scientific Advisory Board](https://www.frontiermeds.com/press-release/frontier-medicines-announces-renowned-physician-scientist-piro-lito-m-d-ph-d-joins-scientific-advisory-board/)
- [Frontier Medicines Announces the Appointment of Monique Bobadilla as Chief People and Culture Officer](https://www.frontiermeds.com/press-release/frontier-medicines-announces-the-appointment-of-monique-bobadilla-as-chief-people-and-culture-officer/)
- [Frontier Medicines Announces Oral Presentation on Dual-Acting Inhibitors of the Active and Inactive Forms of KRAS G12C at the American Association for Cancer Research (AACR) Annual Meeting](https://www.frontiermeds.com/press-release/frontier-medicines-announces-oral-presentation-on-dual-acting-inhibitors-of-the-active-and-inactive-forms-of-kras-g12c-at-the-american-association-for-cancer-research-aacr-annual-meeting/)
- [Frontier Medicines to Present at the Jefferies Healthcare Conference](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-at-the-jefferies-healthcare-conference/)
- [Frontier Medicines Announces Prominent Oncologist Dr. Scott Kopetz Joins its Scientific Advisory Board](https://www.frontiermeds.com/press-release/frontier-medicines-announces-prominent-oncologist-dr-scott-kopetz-joins-its-scientific-advisory-board/)
- [Frontier Medicines Announces Distinguished Oncologist Dr. Pasi Jänne Joins its Scientific Advisory Board](https://www.frontiermeds.com/press-release/frontier-medicines-announces-distinguished-oncologist-dr-pasi-janne-joins-its-scientific-advisory-board/)
- [Frontier Medicines Announces the Appointment of Seasoned Legal Executive Mark Dizon, J.D., as General Counsel](https://www.frontiermeds.com/press-release/frontier-medicines-announces-the-appointment-of-seasoned-legal-executive-mark-dizon-j-d-as-general-counsel/)
- [Frontier Medicines to Present at Credit Suisse 31st Annual Healthcare Conference](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-at-credit-suisse-31st-annual-healthcare-conference/)
- [Frontier Medicines Announces Appointment of Accomplished Finance and Operations Executive, Setareh “SiSi” Pouraghabagher, to Board of Directors](https://www.frontiermeds.com/press-release/frontier-medicines-announces-appointment-of-accomplished-finance-and-operations-executive-setareh-sisi-pouraghabagher-to-board-of-directors/)
- [Frontier Medicines to Present at the 41st Annual J.P. Morgan Healthcare Conference](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference/)
- [Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies](https://www.frontiermeds.com/press-release/frontier-medicines-advances-first-development-candidate-fmc-376-a-uniquely-differentiated-inhibitor-of-both-active-and-inactive-krasg12c-into-ind-enabling-studies/)
- [Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie](https://www.frontiermeds.com/press-release/frontier-medicines-announces-advancement-of-second-and-third-programs-under-global-partnership-with-abbvie/)
- [Frontier Medicines Expands Leadership Team with Addition of Christo Shalish as Head of Business Development](https://www.frontiermeds.com/press-release/frontier-medicines-expands-leadership-team-with-addition-of-christo-shalish-as-head-of-business-development/)
- [Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting](https://www.frontiermeds.com/press-release/frontier-medicines-to-spotlight-lead-candidate-novel-dual-krasg12c-inhibitor-fmc-376-and-the-frontier-platform-at-the-2023-aacr-annual-meeting/)
- [Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting](https://www.frontiermeds.com/press-release/frontier-medicines-presents-new-preclinical-data-on-its-development-candidate-fmc-376-a-dual-krasg12c-inhibitor-at-the-2023-aacr-annual-meeting/)
- [Frontier Medicines Announces Appointment of Andrew Krivoshik, M.D., Ph.D., as Chief Medical Officer](https://www.frontiermeds.com/press-release/frontier-medicines-announces-appointment-of-andrew-krivoshik-m-d-ph-d-as-chief-medical-officer/)
- [Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare Conference](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference/)
- [Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline](https://www.frontiermeds.com/press-release/frontier-medicines-announces-oversubscribed-80-million-series-c-financing-to-support-progress-of-clinical-stage-pipeline/)
- [Frontier Medicines to Participate in Upcoming Investor Conferences](https://www.frontiermeds.com/press-release/frontier-medicines-to-participate-in-upcoming-investor-conferences/)
- [Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-preclinical-data-at-the-american-association-for-cancer-research-annual-meeting-2024/)
- [Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting](https://www.frontiermeds.com/press-release/frontier-medicines-presents-new-data-for-first-in-class-dual-onoff-kras-g12c-inhibitor-fmc-376-at-the-aacr-annual-meeting/)
- [Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension](https://www.frontiermeds.com/press-release/frontier-medicines-appoints-gerardo-ubaghs-as-chief-financial-officer-and-announces-20-million-series-c-extension/)
- [Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor](https://www.frontiermeds.com/press-release/frontier-medicines-announces-milestone-payment-in-abbvie-partnership-following-advancement-of-lead-candidates-targeting-a-historically-undruggable-transcription-factor/)
- [Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential](https://www.frontiermeds.com/press-release/frontier-medicines-announces-fmc-220-the-first-covalent-p53-y220c-activator-development-candidate-with-best-in-class-potential/)
- [Frontier Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference](https://www.frontiermeds.com/press-release/frontier-medicines-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference/)
- [Frontier Medicines Unveils New Preclinical Data for FMC-220, a First-in-Class Covalent p53 Y220C Activator, at AACR 2025](https://www.frontiermeds.com/press-release/frontier-medicines-unveils-new-preclinical-data-for-fmc-220-a-first-in-class-covalent-p53-y220c-activator-at-aacr-2025/)
- [Frontier Medicines to Participate in Two Upcoming March Investor Conferences](https://www.frontiermeds.com/press-release/frontier-medicines-to-participate-in-two-upcoming-march-investor-conferences/)
- [Fierce Biotech: AACR: Verastem, Quanta and Frontier demonstrate KRAS inhibitors' potential in preclinical data](https://www.fiercebiotech.com/research/aacr-verastem-quanta-frontier-and-more-debut-preclinical-data-kras-inhibitors#new_tab)
- [Fierce Biotech: Frontier CEO weathers 'one of the hardest financings' of his career to close $80M series C](https://www.fiercebiotech.com/biotech/frontier-closes-80m-series-c-weathering-one-hardest-financings-ceo-varmas-career#new_tab)
- [San Francisco Business Times: Peninsula biotech raises $80M as it doses 1st person in 1st clinical trial](https://www.bizjournals.com/sanfrancisco/news/2024/02/22/cancer-frontier-medicines-galapagos-kras.html#new_tab)
- [FMC-376 a dual inhibitor of states of KRASG12C is broadly active in PDX models of resistance](https://www.frontiermeds.com/wp-content/uploads/AACR2024FMCPDX.pdf#new_tab)
- [The clinical dual KRASG12C inhibitor FMC-376 has demonstrated potential as both a monotherapy and in combination for the treatment of patients with KRASG12C mutation positive NSCLC](https://www.frontiermeds.com/wp-content/uploads/AACR2024FMC376.pdf#new_tab)
- [Combining Chemoproteomics with Machine Learning Identifies Functional Covalent Fragments for Hard-to-Drug Cancer Drivers](https://www.frontiermeds.com/wp-content/uploads/AACR2023.pdf#new_tab)

## Pages

- [Home](https://www.frontiermeds.com/) - Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies
- [Technologies](https://www.frontiermeds.com/science-platforms/technologies/) - Pairing chemoproteomics with machine learning algorithms, Frontier Medicines finds druggable hotspots and ligands within proteins involved in disease
- [Newsroom](https://www.frontiermeds.com/newsroom/) - Find the latest news, events and resources from Frontier Medicines
- [Footer](https://www.frontiermeds.com/footer/)
- [Contact](https://www.frontiermeds.com/contact/) - Contact Frontier Medicines by phone, email, or US mail for more information
- [Precision-Based](https://www.frontiermeds.com/precision-pipeline/precision-based/) - Frontier Medicines’ therapeutic priorities focus on developing precision medicines for difficult-to-treat cancers
- [Test4](https://www.frontiermeds.com/test4/)
- [test2](https://www.frontiermeds.com/test2/)
- [Test](https://www.frontiermeds.com/test/)
- [FMC-376: KRAS G12C ON+OFF Inhibitor](https://www.frontiermeds.com/precision-pipeline/kras-gtp/) - Frontier Medicines' program is inhibiting both the active and inactive forms of KRAS G12C for potentially differentiated anti-cancer activity
- [Careers](https://www.frontiermeds.com/careers/) - Frontier Medicines is looking for highly qualified people who believe patients come first, science rules, & boldness is the standard operating procedure
- [FMC-242: PI3Kα/RAS breaker](https://www.frontiermeds.com/precision-pipeline/fmc-242b/) - Frontier Medicines' program is inhibiting both the active and inactive forms of KRAS G12C for potentially differentiated anti-cancer activity
- [FMC-220: p53 Y220C activator](https://www.frontiermeds.com/precision-pipeline/fmc-220-p53-y220c-activator/) - Frontier Medicines' program is inhibiting both the active and inactive forms of KRAS G12C for potentially differentiated anti-cancer activity
- [About](https://www.frontiermeds.com/about/) - Get to know the people and scientific philosophy that drives Frontier Medicines to discover & develop precision-based, breakthrough medicines
- [Scientific Approach](https://www.frontiermeds.com/science-platforms/scientific-approach/) - Frontier Medicines uses a proprietary drug discovery engine that enables transformative access to previously undruggable therapeutic targets
- [Press Releases](https://www.frontiermeds.com/newsroom/press-releases/) - Review Frontier Medicines’ complete list of press releases
- [404](https://www.frontiermeds.com/404-page/) - HTML Sitemap
- [Site Map](https://www.frontiermeds.com/site-map/) - HTML Sitemap
- [Privacy Policy](https://www.frontiermeds.com/privacy-policy/)
- [Terms of Use](https://www.frontiermeds.com/terms-of-use/)
- [News Articles](https://www.frontiermeds.com/newsroom/news-articles/) - Read select articles covering Frontier Medicine's news and technologies
- [Precision Pipeline](https://www.frontiermeds.com/precision-pipeline/) - Frontier Medicines is building a pipeline of precision medicines initially focused on oncology
- [Leadership](https://www.frontiermeds.com/about/leadership/) - Get to know the people and scientific philosophy that drives Frontier Medicines to discover & develop precision-based, breakthrough medicines
- [Science & Platforms](https://www.frontiermeds.com/science-platforms/) - Frontier Medicines is making high-impact protein targets accessible to therapeutic intervention through its proprietary platforms

## Team

- [Aaron Weitzman, M.D.](https://www.frontiermeds.com/team/aaron-weitzman/) - Aaron Weitzman, M.D., Chief Medical Officer, Frontier Medicines
- [Cameron Wheeler, Ph.D.](https://www.frontiermeds.com/team/cameron-wheeler/)
- [Chris Varma, Ph.D.](https://www.frontiermeds.com/team/chris-varma-bod/)
- [Sisi Pouraghabagher](https://www.frontiermeds.com/team/sisi-pouraghabagher/)
- [Janwillem Naesens](https://www.frontiermeds.com/team/janwillem-naesens/)
- [Othman Laraki](https://www.frontiermeds.com/team/othman-laraki/)
- [Pamela M. Klein, M.D.](https://www.frontiermeds.com/team/pamela-m-klein/)
- [Derek DiRocco, Ph.D.](https://www.frontiermeds.com/team/derek-dirocco/)
- [David Epstein](https://www.frontiermeds.com/team/david-epstein/)
- [Luke Evnin, Ph.D.](https://www.frontiermeds.com/team/luke-evnin/)
- [David M. Goldstein, Ph.D.](https://www.frontiermeds.com/team/david-m-goldstein/)
- [Giulio Draetta, M.D., Ph.D.](https://www.frontiermeds.com/team/giulio-draetta/)
- [Johannes Hermann, Ph.D.](https://www.frontiermeds.com/team/johannes-hermann/) - Johannes Hermann, Ph.D., Chief Technology Officer, Frontier Medicines
- [Sylvia Mruk](https://www.frontiermeds.com/team/sylvia-mruk/)
- [Mike Preigh](https://www.frontiermeds.com/team/mike-preigh/)
- [Kevin Webster, Ph.D.](https://www.frontiermeds.com/team/kevin-webster/) - Kevin Webster, Ph.D., Chief Scientific Officer, Frontier Medicines
- [Chris Varma, Ph.D.](https://www.frontiermeds.com/team/chris-varma/) - Chris Varma, Ph.D., Chairman and CEO, Frontier Medicines
- [Daniel Erlanson, Ph.D.](https://www.frontiermeds.com/team/daniel-erlanson/) - Daniel Erlanson, Ph.D., Senior Vice President of Innovation and Discovery, Frontier Medicines
- [Gerardo Ubaghs](https://www.frontiermeds.com/team/gerardo-ubaghs/) - George Ubaghs, Chief Financial Officer
- [Scott Kopetz, M.D., Ph.D., FACP](https://www.frontiermeds.com/team/scott-kopetz/)
- [Kevin Koch, Ph.D.](https://www.frontiermeds.com/team/kevin-koch/)
- [Allison Roberts, Ph.D.](https://www.frontiermeds.com/team/allison-roberts-ph-d/)
- [Roberto Zoncu, Ph.D.](https://www.frontiermeds.com/team/roberto-zoncu/)
- [Daniel K. Nomura, Ph.D.](https://www.frontiermeds.com/team/daniel-k-nomura/)
- [Piro Lito, M.D., Ph.D.](https://www.frontiermeds.com/team/piro-lito/)
- [Pasi A. Jänne, M.D., Ph.D.](https://www.frontiermeds.com/team/pasi-a-janne/)
- [William C. Hahn, M.D., Ph.D.](https://www.frontiermeds.com/team/william-c-hahn/)
- [Steven Gygi, Ph.D.](https://www.frontiermeds.com/team/steven-gygi/)
- [Joan S. Brugge, Ph.D.](https://www.frontiermeds.com/team/joan-s-brugge/)

## Categories

- [Publications](https://www.frontiermeds.com/category/publications/)
- [Press Release](https://www.frontiermeds.com/category/press-release/)
- [Media Coverage](https://www.frontiermeds.com/category/media-coverage/)
- [2019](https://www.frontiermeds.com/category/2019/)
- [2020](https://www.frontiermeds.com/category/2020/)
- [2021](https://www.frontiermeds.com/category/2021/)
- [2022](https://www.frontiermeds.com/category/2022/)
- [2023](https://www.frontiermeds.com/category/2023/)
- [2024](https://www.frontiermeds.com/category/2024/)
- [2025](https://www.frontiermeds.com/category/2025/)
- [Featured](https://www.frontiermeds.com/category/featured/)
- [Events](https://www.frontiermeds.com/category/events/)
- [Presentations](https://www.frontiermeds.com/category/presentations/)
- [2026](https://www.frontiermeds.com/category/2026/)

## Therapeutic Areas

- [RAS Pathway](https://www.frontiermeds.com/therapeutic-area/ras-pathway/)
- [Transcription Factors](https://www.frontiermeds.com/therapeutic-area/transcription-factors/)

## Portfolio Categories

- [Scientific Advisory Board](https://www.frontiermeds.com/team/scientific-advisory-board/)
- [Board of Directors](https://www.frontiermeds.com/team/board-of-directors/)
- [Executive Team](https://www.frontiermeds.com/team/executive-team/)
- [Employee](https://www.frontiermeds.com/team/employee/)